<p>Travere Therapeutics, Inc.（纳斯达克代码：TVTX - 获取免费报告）的股票已被目前覆盖该公司的十七家评级机构评定为 “适度买入”，MarketBeat.com 报道。一位投资分析师给予该股票卖出评级，三位给予持有评级，十三位给予买入评级。在过去一年中，发布报告的经纪商对该股票的平均一年目标价为 38.7143 美元。</p>
<p>获取 <strong>Travere Therapeutics</strong> 的提醒：</p>
<ul>
<li>3 家不被关注的医疗公司</li>
</ul>
<p>多家研究机构已对 TVTX 发布报告。杰富瑞金融集团在 9 月 10 日的研究报告中将 Travere Therapeutics 的目标价设定为 35.00 美元。花旗集团在 10 月 31 日的研究报告中将 Travere Therapeutics 的目标价从 34.00 美元上调至 48.00 美元，并给予该公司 “买入” 评级。华尔街禅在周六的研究报告中将 Travere Therapeutics 的评级从 “买入” 上调至 “强力买入”。富国银行在 9 月 11 日的研究报告中将 Travere Therapeutics 的目标价从 27.00 美元上调至 35.00 美元，并给予该公司 “增持” 评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Travere Therapeutics 的 “卖出（e+）” 评级。</p>
<p><strong>获取我们最新的 TVTX 股票报告</strong></p>
<h2>Travere Therapeutics 股票下跌 0.5%</h2>
<ul>
<li>Travere Therapeutics 在鼓舞人心的数据后仍在上升</li>
</ul>
<p>纳斯达克 TVTX 周一开盘价为 34.83 美元。该公司的五十日移动平均价格为 32.08 美元，二百日移动平均价格为 22.92 美元。该股票的市值为 31.2 亿美元，市盈率为-32.86，贝塔系数为 0.89。Travere Therapeutics 的五十二周低点为 12.91 美元，五十二周高点为 37.50 美元。该公司的债务与股本比率为 4.23，流动比率为 2.75，速动比率为 2.71。</p>
<p>Travere Therapeutics（纳斯达克代码：TVTX - 获取免费报告）最近于 10 月 30 日发布了季度财报。该公司报告季度每股收益为 0.28 美元，超出分析师一致预期的-0.31 美元，超出幅度为 0.59 美元。Travere Therapeutics 的股本回报率为-178.68%，净利润率为-20.32%。该公司在本季度的收入为 1.6486 亿美元，而分析师预期为 1.0609 亿美元。去年同期，该公司每股收益为-0.70 美元。Travere Therapeutics 的收入同比增长 162.1%。股票分析师预计 Travere Therapeutics 本财年的每股收益将为-1.4 美元。</p>
<h2>内部买卖</h2>
<p>在其他 Travere Therapeutics 的新闻中，首席会计官 Sandra Calvin 于 11 月 4 日以每股 36.00 美元的平均价格出售了 67,115 股股票，总价值为 2,416,140.00 美元。交易完成后，首席会计官直接持有该公司 48,545 股股票，价值约为 1,747,620 美元。这笔交易代表了他们持有股票的 58.03% 的减少。该交易已在向证券交易委员会提交的文件中披露，您可以通过此链接访问。此外，首席执行官 Eric M. Dube 于 10 月 28 日以每股 30.38 美元的平均价格出售了 92,872 股 Travere Therapeutics 股票，总价值为 2,821,451.36 美元。出售后，首席执行官直接持有该公司 419,173 股股票，价值为 12,734,475.74 美元。这笔交易代表了他们持有股票的 18.14% 的减少。有关此销售的更多详细信息可在官方 SEC 披露中找到。内部人士在过去 90 天内出售了价值 7,910,972 美元的 243,368 股公司股票。内部人士持有公司股票的 4.06%。</p>
<h2>机构资金流入和流出</h2>
<p>多家大型投资者最近增加或减少了对 TVTX 的持股。Penn Capital Management Company LLC 在第三季度将其在 Travere Therapeutics 的持股增加了 39.7%。Penn Capital Management Company LLC 现在拥有 27,004 股该公司的股票，价值 645,000 美元，此前在上个季度增持了 7,680 股。CIBC Bancorp USA Inc. 在第三季度获得了对 Travere Therapeutics 股票的新头寸，价值 225,000 美元。PharVision Advisers LLC 在第三季度购买了对 Travere Therapeutics 股票的新股份，价值 210,000 美元。Voloridge Investment Management LLC 在第三季度将其在 Travere Therapeutics 的持股增加了 18.7%。Voloridge Investment Management LLC 现在拥有 883,672 股该公司的股票，价值 21,120,000 美元，此前在该期间增持了 139,018 股。最后，Quarry LP 在第三季度将其在 Travere Therapeutics 的持股增加了 113.7%。Quarry LP 现在拥有 14,960 股该公司的股票，价值 358,000 美元，此前在该期间增持了 7,960 股。</p>
<h2>Travere Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Travere Therapeutics, Inc. 是一家生物制药公司，致力于识别、开发和提供针对罕见肾脏和代谢疾病的治疗方案。其产品包括 FILSPARI（sparsentan），这是一种每日一次的口服药物，旨在针对 IgA 肾病（内皮素 1 和血管紧张素-II）疾病进展中的两个关键通路；以及 Thiola 和 Thiola EC（tiopronin 片），用于治疗胱氨酸尿症，这是一种罕见的遗传性胱氨酸转运障碍，导致尿液中胱氨酸水平升高和反复肾结石的形成。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，而非 Travere Therapeutics</li>
<li>投资旅游股票的好处</li>
<li>Dave &amp; Buster’s 在双底突破后反转正在进行中</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
<li>3 只值得购买的医疗保健分红股票</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Travere Therapeutics 吗？</h2>
<p>在你考虑 Travere Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Travere Therapeutics 并不在名单上。</p>
<p>虽然 Travere Therapeutics 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TVTX

<p>Travere Therapeutics, Inc.（纳斯达克代码：TVTX）获得了 17 家券商的共识评级为 “适度买入”，平均目标价为 38.71 美元。分析师的评级各不相同，包括卖出、持有和买入。近期内部交易中，首席会计官和首席执行官进行了大量股票出售。机构投资者已调整了在该公司的持股，显著增加了持仓并建立了新头寸</p>

<p>Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) have been assigned a consensus rating of &#34;Moderate Buy&#34; from the seventeen ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $38.7143.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc.（纳斯达克代码：TVTX - 获取免费报告）的股票已被目前覆盖该公司的十七家评级机构评定为 “适度买入”，MarketBeat.com 报道。一位投资分析师给予该股票卖出评级，三位给予持有评级，十三位给予买入评级。在过去一年中，发布报告的经纪商对该股票的平均一年目标价为 38.7143 美元。</p>
</div><p>Get <strong>Travere Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Travere Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>3 Under-the-Radar Healthcare Companies</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家不被关注的医疗公司</li>
</ul>
</div><p>A number of research firms have issued reports on TVTX. Jefferies Financial Group set a $35.00 target price on Travere Therapeutics in a research note on Wednesday, September 10th. Citigroup raised their price target on shares of Travere Therapeutics from $34.00 to $48.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, October 31st. Wall Street Zen upgraded shares of Travere Therapeutics from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday. Wells Fargo &amp; Company increased their price objective on shares of Travere Therapeutics from $27.00 to $35.00 and gave the company an &#34;overweight&#34; rating in a research note on Thursday, September 11th. Finally, Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Travere Therapeutics in a research report on Wednesday, October 8th.</p>
<div class="lb-trans"><p>多家研究机构已对 TVTX 发布报告。杰富瑞金融集团在 9 月 10 日的研究报告中将 Travere Therapeutics 的目标价设定为 35.00 美元。花旗集团在 10 月 31 日的研究报告中将 Travere Therapeutics 的目标价从 34.00 美元上调至 48.00 美元，并给予该公司 “买入” 评级。华尔街禅在周六的研究报告中将 Travere Therapeutics 的评级从 “买入” 上调至 “强力买入”。富国银行在 9 月 11 日的研究报告中将 Travere Therapeutics 的目标价从 27.00 美元上调至 35.00 美元，并给予该公司 “增持” 评级。最后，Weiss Ratings 在 10 月 8 日的研究报告中重申了对 Travere Therapeutics 的 “卖出（e+）” 评级。</p>
</div><p><strong>Get Our Latest Stock Report on TVTX</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 TVTX 股票报告</strong></p>
</div><h2>Travere Therapeutics Stock Down 0.5%</h2>
<div class="lb-trans"><h2>Travere Therapeutics 股票下跌 0.5%</h2>
</div><ul>
<li>Travere Therapeutics Still On The Rise After Encouraging Data</li>
</ul>
<div class="lb-trans"><ul>
<li>Travere Therapeutics 在鼓舞人心的数据后仍在上升</li>
</ul>
</div><p>NASDAQ TVTX opened at $34.83 on Monday. The business has a fifty day moving average price of $32.08 and a two-hundred day moving average price of $22.92. The stock has a market capitalization of $3.12 billion, a PE ratio of -32.86 and a beta of 0.89. Travere Therapeutics has a fifty-two week low of $12.91 and a fifty-two week high of $37.50. The company has a debt-to-equity ratio of 4.23, a current ratio of 2.75 and a quick ratio of 2.71.</p>
<div class="lb-trans"><p>纳斯达克 TVTX 周一开盘价为 34.83 美元。该公司的五十日移动平均价格为 32.08 美元，二百日移动平均价格为 22.92 美元。该股票的市值为 31.2 亿美元，市盈率为-32.86，贝塔系数为 0.89。Travere Therapeutics 的五十二周低点为 12.91 美元，五十二周高点为 37.50 美元。该公司的债务与股本比率为 4.23，流动比率为 2.75，速动比率为 2.71。</p>
</div><p>Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.28 EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.59. Travere Therapeutics had a negative return on equity of 178.68% and a negative net margin of 20.32%.The company had revenue of $164.86 million during the quarter, compared to analysts' expectations of $106.09 million. During the same quarter in the previous year, the firm earned ($0.70) EPS. Travere Therapeutics's revenue was up 162.1% on a year-over-year basis. Equities analysts expect that Travere Therapeutics will post -1.4 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Travere Therapeutics（纳斯达克代码：TVTX - 获取免费报告）最近于 10 月 30 日发布了季度财报。该公司报告季度每股收益为 0.28 美元，超出分析师一致预期的-0.31 美元，超出幅度为 0.59 美元。Travere Therapeutics 的股本回报率为-178.68%，净利润率为-20.32%。该公司在本季度的收入为 1.6486 亿美元，而分析师预期为 1.0609 亿美元。去年同期，该公司每股收益为-0.70 美元。Travere Therapeutics 的收入同比增长 162.1%。股票分析师预计 Travere Therapeutics 本财年的每股收益将为-1.4 美元。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other Travere Therapeutics news, CAO Sandra Calvin sold 67,115 shares of the stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $36.00, for a total value of $2,416,140.00. Following the completion of the transaction, the chief accounting officer directly owned 48,545 shares in the company, valued at approximately $1,747,620. This trade represents a 58.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, CEO Eric M. Dube sold 92,872 shares of Travere Therapeutics stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $30.38, for a total value of $2,821,451.36. Following the sale, the chief executive officer directly owned 419,173 shares in the company, valued at $12,734,475.74. The trade was a 18.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 243,368 shares of company stock worth $7,910,972 in the last ninety days. Insiders own 4.06% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Travere Therapeutics 的新闻中，首席会计官 Sandra Calvin 于 11 月 4 日以每股 36.00 美元的平均价格出售了 67,115 股股票，总价值为 2,416,140.00 美元。交易完成后，首席会计官直接持有该公司 48,545 股股票，价值约为 1,747,620 美元。这笔交易代表了他们持有股票的 58.03% 的减少。该交易已在向证券交易委员会提交的文件中披露，您可以通过此链接访问。此外，首席执行官 Eric M. Dube 于 10 月 28 日以每股 30.38 美元的平均价格出售了 92,872 股 Travere Therapeutics 股票，总价值为 2,821,451.36 美元。出售后，首席执行官直接持有该公司 419,173 股股票，价值为 12,734,475.74 美元。这笔交易代表了他们持有股票的 18.14% 的减少。有关此销售的更多详细信息可在官方 SEC 披露中找到。内部人士在过去 90 天内出售了价值 7,910,972 美元的 243,368 股公司股票。内部人士持有公司股票的 4.06%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of large investors have recently added to or reduced their stakes in TVTX. Penn Capital Management Company LLC grew its holdings in Travere Therapeutics by 39.7% during the 3rd quarter. Penn Capital Management Company LLC now owns 27,004 shares of the company's stock worth $645,000 after acquiring an additional 7,680 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new position in shares of Travere Therapeutics during the third quarter worth $225,000. PharVision Advisers LLC bought a new stake in shares of Travere Therapeutics in the third quarter worth $210,000. Voloridge Investment Management LLC increased its holdings in Travere Therapeutics by 18.7% in the third quarter. Voloridge Investment Management LLC now owns 883,672 shares of the company's stock valued at $21,120,000 after purchasing an additional 139,018 shares during the period. Finally, Quarry LP increased its holdings in Travere Therapeutics by 113.7% in the third quarter. Quarry LP now owns 14,960 shares of the company's stock valued at $358,000 after purchasing an additional 7,960 shares during the period.</p>
<div class="lb-trans"><p>多家大型投资者最近增加或减少了对 TVTX 的持股。Penn Capital Management Company LLC 在第三季度将其在 Travere Therapeutics 的持股增加了 39.7%。Penn Capital Management Company LLC 现在拥有 27,004 股该公司的股票，价值 645,000 美元，此前在上个季度增持了 7,680 股。CIBC Bancorp USA Inc. 在第三季度获得了对 Travere Therapeutics 股票的新头寸，价值 225,000 美元。PharVision Advisers LLC 在第三季度购买了对 Travere Therapeutics 股票的新股份，价值 210,000 美元。Voloridge Investment Management LLC 在第三季度将其在 Travere Therapeutics 的持股增加了 18.7%。Voloridge Investment Management LLC 现在拥有 883,672 股该公司的股票，价值 21,120,000 美元，此前在该期间增持了 139,018 股。最后，Quarry LP 在第三季度将其在 Travere Therapeutics 的持股增加了 113.7%。Quarry LP 现在拥有 14,960 股该公司的股票，价值 358,000 美元，此前在该期间增持了 7,960 股。</p>
</div><h2>Travere Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Travere Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc. 是一家生物制药公司，致力于识别、开发和提供针对罕见肾脏和代谢疾病的治疗方案。其产品包括 FILSPARI（sparsentan），这是一种每日一次的口服药物，旨在针对 IgA 肾病（内皮素 1 和血管紧张素-II）疾病进展中的两个关键通路；以及 Thiola 和 Thiola EC（tiopronin 片），用于治疗胱氨酸尿症，这是一种罕见的遗传性胱氨酸转运障碍，导致尿液中胱氨酸水平升高和反复肾结石的形成。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Travere Therapeutics</li>
<li>Investing in Travel Stocks Benefits</li>
<li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li>
<li>Best Energy Stocks - Energy Stocks to Buy Now</li>
<li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li>
<li>3 Healthcare Dividend Stocks to Buy</li>
<li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 Travere Therapeutics</li>
<li>投资旅游股票的好处</li>
<li>Dave &amp; Buster’s 在双底突破后反转正在进行中</li>
<li>最佳能源股票 - 现在值得购买的能源股票</li>
<li>3 只在 10 年期国债利率上升时值得购买的金融股票</li>
<li>3 只值得购买的医疗保健分红股票</li>
<li>迪士尼的 10 亿美元交易将其魔力带入 OpenAI</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TVTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Travere Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Travere Therapeutics 吗？</h2>
</div><p>Before you consider Travere Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Travere Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Travere Therapeutics 并不在名单上。</p>
</div><p>While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Travere Therapeutics 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Travere Therapeutics, Inc.（纳斯达克股票代码：TVTX）被券商给予平均评级为 “适度买入”